Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres

被引：0
|
作者：
Toellner, H. [1 ]
Beswick, W. [2 ]
Crooks, M. [2 ]
Donaldson, C. [3 ]
Forrest, I. [3 ]
Hart, S. [2 ]
Leonard, C.
Major, M. [2 ]
Simpson, A. [3 ]
Chaudhuri, N. [4 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England
[3] Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Hosp South Manchester, Wythenshawe, Scotland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5384
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
    Toellner, Hannah
    Hughes, G.
    Beswick, W.
    Crooks, M. G.
    Donaldson, C.
    Forrest, I.
    Hart, S. P.
    Leonard, C.
    Major, M.
    Simpson, A. J.
    Chaudhuri, N.
    CLINICAL AND TRANSLATIONAL MEDICINE, 2017, 6
  • [2] Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres
    Toellner, Hannah
    Beswick, W.
    Crooks, M. G.
    Donaldson, C.
    Forrest, I.
    Hart, S. P.
    Leonard, C.
    Major, M.
    Simpson, A. J.
    Chaudhuri, N.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [3] NINTEDANIB FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - INITIAL CLINICAL EXPERIENCE IN A UK COHORT
    Fletcher, S. V.
    Jones, M. G.
    Renzoni, E.
    Parfrey, H.
    Hoyles, R.
    Spinks, K.
    Kokosi, M.
    Kwok, A.
    Warburton, C.
    Titmuss, V.
    Maher, T.
    Chua, F.
    Wells, A.
    Richeldi, L.
    Spencer, L. G.
    THORAX, 2015, 70 : A78 - A78
  • [4] Pirfenidone and Nintedanib Therapy for Idiopathic Pulmonary Fibrosis: A Tertiary Centre Experience
    Diab, N.
    Mao, T.
    Danoff, S. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [5] Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted
    Mura, Marco
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2021, 66
  • [6] DELIVERY OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROTIC INTERSTITIAL LUNG DISEASE: EXPERIENCE FROM A UK TERTIARY CENTRE
    Martinovic, J. L.
    Nagvi, M.
    West, A.
    THORAX, 2022, 77 : A95 - A96
  • [7] Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain
    Valenzuela, Claudia
    Molina, Maria Molina
    Portal, Jose Antonio Rodriguez
    Ortiz, Romero
    Cano, Esteban
    Nieto, Maria Jesus Rodriguez
    Laporta, Rosalia
    Ancochea, Julio
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [8] Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis
    Aldhaheri, Sharina
    Moran-Mendoza, Onofre
    Mccarthy, Lynda
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [9] SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS
    Highland, Kristin
    Distler, Oliver
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Kohlbrenner, Veronika
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Kuwana, Masataka
    Maher, Toby M.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 200 - 200
  • [10] NATIONAL UK EXPERIENCE OF THE TREATMENT OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE WITH NINTEDANIB
    Dixon, G.
    Hague, S.
    Thould, H.
    Khin, A. M. N.
    Mulholland, S.
    Gibbons, M.
    Barratt, S. L.
    THORAX, 2023, 78 (SUPPL_4) : A11 - A12
12345